A fixed-dose combination (FDC) antihypertensive medication containing an angiotensin II receptor blocker (ARB), Olmesartan Medoxomil, and a dihydropyridine calcium channel blocker (CCB), Amlodipine. This combination provides synergistic blood pressure lowering through complementary mechanisms, offering improved efficacy and tolerability compared to monotherapy. It is a first-line treatment for essential hypertension in patients requiring more than one drug to achieve target BP.
Adult: One tablet (Olmesartan 40mg + Amlodipine 5mg) orally once daily. Dose may be titrated after 2-4 weeks. Maximum: Olmesartan 40mg + Amlodipine 10mg daily.
Note: Can be taken with or without food. Swallow whole with a glass of water. Administer at the same time each day, preferably in the morning. Do not crush or chew. Dose is not influenced by food.
Combined blockade of the Renin-Angiotensin-Aldosterone System (RAAS) and inhibition of vascular smooth muscle calcium influx. Olmesartan selectively blocks the binding of angiotensin II to the AT1 receptor, preventing vasoconstriction, aldosterone secretion, and sympathetic activation. Amlodipine inhibits transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, causing peripheral arterial vasodilation and reduced peripheral vascular resistance.
Pregnancy: CATEGORY C (1st trimester) and CATEGORY D (2nd & 3rd trimesters). Drugs that act directly on the RAAS can cause injury and death to the developing fetus. Discontinue as soon as pregnancy is detected. Olmesartan is contraindicated in 2nd and 3rd trimester.
Driving: May cause dizziness, headache, fatigue, or somnolence, especially at initiation. Patients should not drive or operate machinery until they know how the medication affects them.
| Other Antihypertensives (Diuretics, Beta-blockers) | Additive hypotensive effect; risk of severe hypotension. | Major |
| Potassium supplements / Potassium-sparing diuretics (Spironolactone, Eplerenone) | Increased risk of hyperkalemia. | Major |
| NSAIDs (e.g., Ibuprofen, Diclofenac) | May reduce antihypertensive effect and increase risk of renal impairment, especially in elderly/volume-depleted. | Major |
| Lithium | Olmesartan may increase lithium levels and toxicity. Monitor serum lithium. | Major |
| Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin, Ritonavir) | Increase Amlodipine plasma concentration, risk of hypotension and edema. | Moderate |
| Simvastatin | Amlodipine may increase simvastatin exposure, increasing risk of myopathy. Limit simvastatin dose to 20mg daily. | Moderate |
| Sildenafil, Tadalafil (for PAH) | Additive hypotensive effect. | Moderate |
| Aliskiren | Increased risk of hypotension, hyperkalemia, and renal impairment. Contraindicated in diabetes/renal impairment. | Major |
Same composition (Olmesartan Medoxomil (40mg) + Amlodipine (5mg)), different brands: